

Specialty Guideline Management-FEHB

Zoladex

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Zoladex	goserelin acetate

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications^{1,2}

Prostate Cancer

- For use in combination with flutamide for the management of locally confined stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with Zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
- In the palliative treatment of advanced carcinoma of the prostate.

Endometriosis

For the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with Zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months. (Zoladex 3.6 mg strength only)

Endometrial Thinning

For use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. (Zoladex 3.6 mg strength only)

Reference number(s)
7009-A

Advanced Breast Cancer

For use in the palliative treatment of advanced breast cancer in pre-and perimenopausal women. (Zoladex 3.6 mg strength only)

Compendial Uses

- Breast cancer^{3,8}
- Prostate cancer³
- Ovarian cancer³
- Gender dysphoria (also known as transgender and gender diverse [TGD] persons)⁴⁻⁷
- Preservation of ovarian function^{4,9-12}
- Prevention of recurrent menstrual related attacks in acute porphyria^{13,14}
- Treatment of chronic anovulatory uterine bleeding with severe anemia⁴
- Androgen receptor positive salivary gland tumors¹⁶
- Uterine Sarcoma³

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review: Hormone receptor status testing results (where applicable).

Exclusions

Coverage will not be provided for members with any of the following exclusions: Use of the 10.8 mg strength for diagnoses other than prostate cancer, breast cancer, and gender dysphoria.

Prescriber Specialties^{13,14}

For prevention of recurrent menstrual related attacks in acute porphyria, this medication must be prescribed by or in consultation with a provider experienced in the management of porphyrias.

Coverage Criteria

Breast Cancer^{1,3,8}

Authorization of 12 months may be granted for the treatment of hormone receptor-positive breast cancer.

Prostate Cancer¹⁻³

Authorization of 12 months may be granted for treatment of prostate cancer.

Ovarian Cancer^{3,16}

Authorization of 12 months may be granted as a single agent for treatment of persistent or recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer, malignant sex cord-stromal tumor, carcinosarcoma (malignant mixed Müllerian tumor), clear cell carcinoma of the ovary, mucinous carcinoma of the ovary, grade 1 endometrioid carcinoma and low grade serous carcinoma.

Endometriosis¹

Authorization of a total of 6 months may be granted to members for treatment of endometriosis.

Endometrial-Thinning Agent^{1,4}

Authorization of 2 doses may be granted for endometrial thinning prior to endometrial ablation or resection for dysfunctional uterine bleeding.

Authorization of a total of 6 months may be granted for treatment of chronic anovulatory uterine bleeding with severe anemia.

Gender Dysphoria^{4-7,18}

Authorization of 12 months may be granted for gender transition when all of the following criteria are met:

- The member has a diagnosis of gender dysphoria.
- Member is at least 19 years of age or older.
- The member is able to make an informed decision to engage in treatment.
- The member will receive the requested medication concomitantly with gender-affirming hormones.
- The member's comorbid conditions are reasonably controlled.
- The member has been educated on any contraindications and side effects to therapy.
- The member has been informed of fertility preservation options.

Preservation of Ovarian Function^{4,9-12}

Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

Prevention of Recurrent Menstrual Related Attacks in Acute Porphyria^{13,14}

Authorization of 12 months may be granted for prevention of recurrent menstrual related attacks in members with acute porphyria.

Salivary Gland Tumors¹⁷

Authorization of 12 months maybe be granted for treatment of recurrent, unresectable, or metastatic salivary gland tumor as a single agent or in combination with abiraterone and prednisone when the tumor is androgen receptor positive.

Uterine Sarcoma³

Authorization of 12 months may be granted for treatment of uterine sarcoma in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) when the member is premenopausal and not suitable for surgery.

Continuation of Therapy

Breast Cancer and Ovarian Cancer^{1,3,8,16}

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy and who have not experienced an unacceptable toxicity.

Prostate Cancer¹⁻³

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL) and who have not experienced an unacceptable toxicity.

Gender Dysphoria^{15,18}

Authorization of 12 months may be granted for continued treatment for gender transition in members requesting reauthorization when all of the following criteria are met:

- The member has a diagnosis of gender dysphoria.
- Member is at least 19 years of age or older.
- The member is able to make an informed decision to engage in treatment.
- The member will receive the requested medication concomitantly with gender-affirming hormones.
- The member's comorbid conditions are reasonably controlled.
- The member has been educated on any contraindications and side effects to therapy.
- Before the start of therapy, the member has been informed of fertility preservation options.

Salivary Gland Tumor and Uterine Sarcoma^{3,17}

Authorization of 12 months may be granted for continued treatment of salivary gland tumor and uterine sarcoma in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

All Other Indications

All members (including new members) requesting authorization for continuation of therapy for the specified indications below must meet all requirements in the coverage criteria section:

- Endometriosis

Reference number(s)
7009-A

- Endometrial-thinning agent
- Preservation of ovarian function
- Prevention of recurrent menstrual related attacks in acute porphyria

References

1. Zoladex 3.6 mg [package insert]. Deerfield, IL: TerSera Therapeutics LLC; March 2023.
2. Zoladex 10.8 mg [package insert]. Deerfield, IL: TerSera Therapeutics LLC; December 2020.
3. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 18, 2025.
4. DRUGDEX® System (electronic version). Truven Health Analytics, Ann Arbor, MI. Available at <http://www.micromedexsolutions.com>. Accessed February 18, 2025.
5. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869–3903.
6. Gender Identity Research and Education Society. Guidance for GPs and other clinicians on the treatment of gender variant people. UK Department of Health. Published March 10, 2008.
7. Coleman E, Radix AE, Brown GR, et al. Standards of care for the health of transgender and gender diverse people, version 8. 2022;23(Suppl 1):S1-S259. doi: 10.1080/26895269.2022.2100644.
8. Noguchi S, Kim HJ, Jesena A, et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. *Breast Cancer (Tokyo, Japan)*. 2016;23(5):771-779. doi:10.1007/s12282-015-0637-4.
9. Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015;372:923-32. doi:10.1056/NEJMoa1413204.
10. Clowse MEB, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. *J Womens Health (Larchmt)*. 2009;18(3): 311–319. doi:10.1089/jwh.2008.0857.
11. Oktay K, Harvey BE, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36(19):1994-2003.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2025. https://www.nccg.org/professionals/physician_gls/pdf/breast.pdf. Accessed February 6, 2024.
13. Stein P, Badminton M, Barth J, et al. British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. *Ann Clin Biochem*. 2013 ;50(Pt 3):217-23.
14. Innala E, Bäckström T, Bixo M, et al. Evaluation of gonadotrophin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. *Acta Obstet Gynecol Scand*. 2010;89:95–100.
15. Health Care for Transgender and Gender Diverse Individuals. ©2021 The American College of Obstetricians and Gynecologists. Available at: <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/03/health-care-for-transgender-and-gender-diverse-individuals>.

Reference number(s)
7009-A

16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed February 18, 2025.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2.2025. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed February 18, 2025.
18. FEHB Program Carrier Letter. Letter Number 2025-01A. <https://www.opm.gov/healthcare-insurance/carriers/fehb/2025/2025-1a.pdf>. Accessed May 15, 2025.